Vericel Corporation
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the … Read more
Vericel Corporation (ATQP) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.069x
Based on the latest financial reports, Vericel Corporation (ATQP) has a cash flow conversion efficiency ratio of 0.069x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€22.08 Million) by net assets (€321.86 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Vericel Corporation - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Vericel Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Vericel Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vericel Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nektar Therapeutics
NASDAQ:NKTR
|
-0.573x |
|
Fujian Huoju Electronic
SHG:603678
|
-0.005x |
|
American Superconductor Corporation
NASDAQ:AMSC
|
0.006x |
|
LIVZON PHARMAC. GRP H YC1
F:LP6
|
N/A |
|
Jiangsu Dingsheng New Material Joint-Stock Co Ltd
SHG:603876
|
0.012x |
|
JUSUNG ENGINEERING Co. Ltd
KQ:036930
|
-0.027x |
|
SIGMAROC PLC LS -01
F:M2I2
|
N/A |
|
Columbia Sportswear Company
NASDAQ:COLM
|
0.360x |
Annual Cash Flow Conversion Efficiency for Vericel Corporation (2014–2024)
The table below shows the annual cash flow conversion efficiency of Vericel Corporation from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €291.97 Million | €58.16 Million | 0.199x | +27.47% |
| 2023-12-31 | €225.95 Million | €35.31 Million | 0.156x | +69.89% |
| 2022-12-31 | €192.27 Million | €17.69 Million | 0.092x | -46.00% |
| 2021-12-31 | €170.46 Million | €29.04 Million | 0.170x | +30.17% |
| 2020-12-31 | €134.26 Million | €17.57 Million | 0.131x | +302.42% |
| 2019-12-31 | €111.09 Million | €-7.18 Million | -0.065x | -1504.40% |
| 2018-12-31 | €102.23 Million | €-412.00K | -0.004x | +99.31% |
| 2017-12-31 | €22.54 Million | €-13.18 Million | -0.585x | +27.35% |
| 2016-12-31 | €24.71 Million | €-19.89 Million | -0.805x | -33.50% |
| 2015-12-31 | €22.13 Million | €-13.35 Million | -0.603x | +15.41% |
| 2014-12-31 | €35.64 Million | €-25.41 Million | -0.713x | -- |